Psychedelic Research Bulletin: February 2023 Post published:March 24, 2023 Post category:Psychedelics Research Review
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights Post published:March 24, 2023 Post category:Press Release
Psyence Group Announces Cantheon Capital Private Placement Post published:March 23, 2023 Post category:Press Release
Field Trip Health & Wellness Obtains CCAA Protection Post published:March 22, 2023 Post category:Press Release
Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article Post published:March 22, 2023 Post category:Press Release
Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023 Post published:March 22, 2023 Post category:Press Release
Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023 Post published:March 21, 2023 Post category:Press Release
Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery Post published:March 21, 2023 Post category:Press Release
Psyence Partners with iNGENÅ« for Palliative Care Clinical Trial in Australia Post published:March 21, 2023 Post category:Press Release
Algernon Pharmaceuticals Announces Launch of Rights Offering Post published:March 21, 2023 Post category:Press Release